Published in Pharma Investments, Ventures and Law Weekly, December 26th, 2004
For the third quarter of fiscal 2004, BDSI reported total revenue of approximately $665,000, compared to revenue of approximately $780,000 for the same period in fiscal 2003.
However, BDSI reported its first quarterly profit, slightly in excess of $1 million, or $0.14 per share, due in part to a one-time $2.5 million asset sale (consisting of a future royalty revenue stream) to Accentia Biopharmaceuticals, Inc., a related...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly